10-Q: Stemtech Faces Going Concern Doubt Amidst Sales Decline

Stemtech Corporation reported a significant net sales decline and recurring losses, raising substantial doubt about its ability to continue as a going concern, despite cost-cutting and strategic expansion efforts.

Summary

• Net sales for the three months ended September 30, 2025, decreased by 17.4% to $852,300 from $1,031,630 in the prior year.
• Net sales for the nine months ended September 30, 2025, fell by 35.3% to $2,418,271 from $3,740,000 in the prior year.
• The company reported a net loss of $812,541 for the three months ended September 30, 2025, an improvement from a $1,171,405 net loss in the same period last year.
• For the nine months ended September 30, 2025, the net loss was $2,567,547, an improvement from a $3,376,121 net loss in the prior year.
• Stemtech has an accumulated deficit of approximately $33.4 million and a working capital deficiency of approximately $9.2 million as of September 30, 2025.
• Management has concluded that these factors raise substantial doubt about the company's ability to continue as a going concern for at least the next twelve months.
• The company is actively pursuing a private placement of common stock to raise $5-7 million by Q4 2025 and a convertible debt facility of up to $3 million by Q1 2026.
• Cost reduction initiatives are expected to save approximately $0.5 million per year, with potential for an additional $1.0 million annually in contingency actions.
• Strategic initiatives include a joint venture in India (51% ownership) and an exclusive distribution and licensing agreement in Taiwan.
• The number of authorized common stock shares was increased to 1,500,000,000 from 400,000,000 effective October 31, 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including significant sales declines, recurring losses, a substantial working capital deficiency, and explicit 'going concern' doubt. Defaults on debt and uncommitted capital raise plans add to the high risk, outweighing operational cost reductions and strategic initiatives.

Positives

• Gross profit for the three months ended September 30, 2025, increased by 4.8% to $682,483, despite lower sales, due to efficiency improvements and cost management.
• Operating expenses decreased significantly by 25.3% to $1,021,700 for the three months and by 25.5% to $3,799,873 for the nine months ended September 30, 2025, reflecting effective cost management.
• Operating loss improved by $377,253 for the three months and by $574,480 for the nine months ended September 30, 2025, compared to the prior year periods.
• Net loss decreased by $358,864 for the three months and by $808,574 for the nine months ended September 30, 2025, primarily due to lower operating expenses.
• The company launched new products in 2025, including Cellect One Shield HOCL (Hypochlorous Acid Skin Care) and StemPets (Nutritional supplement for dogs and cats).
• Strategic expansion into new international markets through a joint venture in India and a licensing agreement in Taiwan is expected to enhance brand visibility and diversify revenue streams.
• Outsourcing U.S. order fulfillment and customer service to Mexico, effective August 7, 2023, has significantly reduced costs.

Negatives

• Net sales declined by 17.4% for the three months and 35.3% for the nine months ended September 30, 2025, attributed to a strategic shift and limited working capital.
• The company has incurred recurring operating losses and negative cash flows from operations since inception.
• An accumulated deficit of approximately $33.4 million and a working capital deficiency of approximately $9.2 million as of September 30, 2025, indicate severe financial distress.
• Substantial doubt exists about the company's ability to continue as a going concern for at least the next twelve months.
• The company is in default under certain Merchant Cash Advance (MCA) financing agreements, leading to legal proceedings by lenders.
• Cash flows used in operating activities increased to $610,584 for the nine months ended September 30, 2025, from $330,278 a year earlier.
• The capital raise and convertible debt financing plans are not yet committed, and certain cost-reduction initiatives are not fully implemented, meaning the mitigation plans are not guaranteed to alleviate going concern doubt.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring operating losses, negative cash flows, and a significant working capital deficiency.
• Dependence on external financing, including equity and convertible debt issuances, which may not be available on acceptable terms or at all.
• Potential for significant dilution to current shareholders from future equity or convertible debt issuances.
• Default under certain Merchant Cash Advance (MCA) financing agreements, leading to legal proceedings and potential acceleration of payments, further impacting liquidity.
• Inability to estimate additional losses beyond the accrued $267,000 for the former CEO lawsuit, and potential for increased legal expenses.
• Liquidity constraints limiting the company's ability to replenish inventory and fulfill orders on a timely basis, impacting sales.
• Reliance on the success of uncommitted capital raising efforts and unproven revenue enhancement initiatives to improve financial condition.
• Potential conflicts of interest and dilution risks associated with related-party financing and equity-based compensation to executives and directors.
• Market conditions and investor participation for capital raising activities are not entirely within the company's control.

Future Outlook

Management expects to recapture deferred sales, restore fulfillment cycles, and resume sequential revenue growth once inventory financing and additional working capital arrangements are implemented. The company anticipates continued growth in the overall stem cell global market, projected to reach $30 billion by 2030, positioning Stemtech for growth as awareness increases. They plan to expand into new international markets starting Q1 2026 and project quarterly revenue increases of 15-20% relative to Q3 2025 through distributor network growth and joint ventures. However, the company explicitly states that its ability to execute these plans is subject to market conditions and investor participation not entirely within its control, and substantial doubt about its ability to continue as a going concern is not alleviated.

Management Comments

• The current quarter reflects the company's ongoing shift toward streamlining operations and focusing on long-term distributor quality and sustainability rather than short-term volume growth.
• This period of recalibration has allowed us to focus resources on core, high-performing markets and reduce dependency on lower-margin geographies and begin implementing improvements in customer engagement and retention tools, which are expected to yield benefits in upcoming quarters.
• The decline in net sales for the period is largely attributable to the company's ongoing transformation as we continue to prioritize long-term distributor quality and operational efficiency over short-term volume growth.
• Management believes that the sales decline reflects timing and capital constraints rather than a reduction in market demand.
• We are optimistic about the long-term benefits of this recalibration, which includes strengthened customer engagement and retention programs that are expected to contribute to sustainable growth in future quarters.
• Management is actively pursuing inventory financing and additional working capital arrangements to normalize production and inventory availability.
• The company remains confident in its ability to achieve long-term growth objectives as funding constraints are resolved and global distribution continues to expand.
• Management believes the terms of related-party transactions were reasonable given the company's financial condition and represent the most practical sources of capital during the periods presented.

Industry Context

Stemtech operates in the global network marketing and stem cell nutrition industry. The company positions itself as a pioneer in stem cell science, offering products that enhance the function of the body's natural stem cells. The filing highlights the overall stem cell global market, including therapy and pharma, is projected to reach $30 billion by 2030, suggesting a growing market opportunity. Stemtech's strategic shift towards a Direct-to-Consumer (DTC) model and international joint ventures aligns with broader trends in the wellness and direct selling industries seeking to leverage e-commerce and expand global reach. However, the company's significant financial challenges and liquidity constraints contrast with the potential growth in the broader stem cell market, indicating an inability to capitalize on industry trends without substantial capital infusion.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• A lawsuit filed by the former CEO (prior to the company's bankruptcy proceedings) against Stemtech HealthSciences Corp. for approximately $267,000 in unpaid salary and vacation pay is ongoing. The company has accrued $267,000 related to this matter and considers the claims without merit.
• The company is in default under certain Merchant Cash Advance (MCA) financing agreements, and lenders have filed legal proceedings seeking recovery of outstanding balances. The full outstanding balances are reflected as liabilities, and management believes any loss above recorded amounts is reasonably possible, but unquantifiable at this time.

Related Party Transactions

• John W. Meyer, President and COO, provided a short-term working capital loan of $105,000 in 2024 and an additional $25,000 on February 20, 2025, both bearing 18% interest, unsecured, and payable on demand. The aggregate related-party loan balance, including accrued interest, totaled $147,610 as of September 30, 2025.
• As of September 30, 2025, the company owed outstanding principal balances of convertible promissory notes of $141,964 to Mr. John W. Meyer and $25,000 to Director Mr. Darryl V. Green.
• On March 19, 2024, the company issued 900,000 shares to the Chief Financial Officer as equity compensation, valued at $45,000 ($0.05 per share).
• On March 19, 2024, the company issued 5,000,000 shares (1,000,000 each to five directors) valued at $150,000 ($0.05 per share) as stock-based compensation for director services.
• For the nine months ended September 30, 2025, the company recognized $328,388 of compensation expense related to previously granted awards to the Chairman and CEO.
• On March 6, 2025, the company issued 5,000,000 shares (1,000,000 each to five directors) valued at $150,000 ($0.03 per share) for board service during the period.
• All related-party transactions were reviewed and approved by the independent members of the Board of Directors.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future equity raises and existing equity-based compensation. The 'going concern' doubt poses a substantial risk to the value of their investment. The increase in authorized shares to 1.5 billion further enables dilution.
• **Employees:** Potential for further headcount reductions if contingency cost-saving actions are implemented due to capital raising delays or lower-than-expected proceeds.
• **Customers:** May experience continued delays in order fulfillment due to limited working capital and inventory constraints, potentially impacting satisfaction and retention.
• **Suppliers:** May face delayed payments or renegotiated terms due to the company's liquidity constraints.
• **Creditors:** Lenders under Merchant Cash Advance agreements are already pursuing legal action due to defaults, indicating a high risk of non-payment or delayed repayment for other creditors. Convertible note holders, including related parties, also face uncertainty regarding repayment or conversion terms.

Next Steps

• Actively pursue a private placement of common stock to raise approximately $5-7 million by Q4 2025.
• Negotiate and close a convertible debt facility of up to $3 million by Q1 2026.
• Implement identified cost reductions of approximately $0.5 million per year, with potential for an additional $1.0 million annually.
• Expand into new international markets beginning Q1 2026.
• Continue growth of distributor networks, projected to increase quarterly revenues by 15-20% relative to Q3 2025.
• Pursue joint venture arrangements to produce incremental revenue with minimal capital outlay.
• Actively evaluate strategic alternatives, including potential partnerships, licensing opportunities, and other transactions for additional liquidity.
• Engage in ongoing discussions with MCA lenders to negotiate potential settlements or restructuring of obligations.
• Continue to defend against the former CEO's lawsuit.

Key Dates

Recommendation

Stemtech Corporation is in a precarious financial position, explicitly stating 'substantial doubt about the Company's ability to continue as a going concern is not alleviated.' The company has a significant accumulated deficit, a large working capital deficiency, and has defaulted on debt obligations, leading to legal proceedings. While management has outlined mitigation plans, including capital raises and cost reductions, these are not yet committed or fully implemented, and their success is uncertain. The substantial decline in net sales, coupled with increased cash burn from operations, indicates a deteriorating core business. The high risk of further dilution from potential equity raises and the ongoing liquidity crisis make the stock a 'strong sell' for any investor.

Keywords

Stemtech Corporation, 10-Q, Quarterly Report, SEC Filing, Financial Results, Net Sales, Net Loss, Going Concern, Liquidity, Capital Raise, Convertible Debt, Operating Expenses, Cost of Goods Sold, Working Capital Deficiency, Merchant Cash Advance, Legal Proceedings, Related Party Transactions, Stem Cell Nutrition, Direct Selling, Network Marketing, International Expansion, India Joint Venture, Taiwan Licensing, DTC Strategy, STEK